Daxdilimab

Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2].

Product Specifications

CAS Number

[2245966-28-1]

Product Name Alternative

MEDI7734; VIB7734

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/daxdilimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Daxdilimab]

Molecular Weight

(144.38 kDa)

References & Citations

[1]Patel S, et al. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021 Feb;7 (2) :e06158.|[2]Retamozo S, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opin Pharmacother. 2021 Dec;22 (17) :2359-2371.